244 related articles for article (PubMed ID: 26816112)
1. Tuberous sclerosis--A model for tumour growth.
Dodd KM; Dunlop EA
Semin Cell Dev Biol; 2016 Apr; 52():3-11. PubMed ID: 26816112
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.
Medvetz D; Priolo C; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
6. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
[TBL] [Abstract][Full Text] [Related]
7. Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases.
Kassai H; Sugaya Y; Noda S; Nakao K; Maeda T; Kano M; Aiba A
Cell Rep; 2014 Jun; 7(5):1626-1639. PubMed ID: 24857653
[TBL] [Abstract][Full Text] [Related]
8. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
9. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
Tee AR; Sampson JR; Pal DK; Bateman JM
Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
[TBL] [Abstract][Full Text] [Related]
10. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.
Li J; Csibi A; Yang S; Hoffman GR; Li C; Zhang E; Yu JJ; Blenis J
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E21-9. PubMed ID: 25524627
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex (TSC).
Niere F; Namjoshi S; Song E; Dilly GA; Schoenhard G; Zemelman BV; Mechref Y; Raab-Graham KF
Mol Cell Proteomics; 2016 Feb; 15(2):426-44. PubMed ID: 26419955
[TBL] [Abstract][Full Text] [Related]
13. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.
Howell JJ; Hellberg K; Turner M; Talbott G; Kolar MJ; Ross DS; Hoxhaj G; Saghatelian A; Shaw RJ; Manning BD
Cell Metab; 2017 Feb; 25(2):463-471. PubMed ID: 28089566
[TBL] [Abstract][Full Text] [Related]
14. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
15. mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.
Polchi A; Magini A; Meo DD; Tancini B; Emiliani C
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772672
[TBL] [Abstract][Full Text] [Related]
16. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
17. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
[TBL] [Abstract][Full Text] [Related]
18. Impaired Mitochondrial Dynamics and Mitophagy in Neuronal Models of Tuberous Sclerosis Complex.
Ebrahimi-Fakhari D; Saffari A; Wahlster L; Di Nardo A; Turner D; Lewis TL; Conrad C; Rothberg JM; Lipton JO; Kölker S; Hoffmann GF; Han MJ; Polleux F; Sahin M
Cell Rep; 2016 Oct; 17(4):1053-1070. PubMed ID: 27760312
[TBL] [Abstract][Full Text] [Related]
19. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
20. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.
Taneike M; Nishida K; Omiya S; Zarrinpashneh E; Misaka T; Kitazume-Taneike R; Austin R; Takaoka M; Yamaguchi O; Gambello MJ; Shah AM; Otsu K
PLoS One; 2016; 11(3):e0152628. PubMed ID: 27023784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
